Researchers at MIT, SMART, and collaborators developed the first fluorescent nanosensor capable of rapidly detecting indole-3-propionic acid (IPA), a gut microbiome metabolite linked to inflammation, IBD, diabetes, and liver disease. Unlike traditional mass spectrometry, the sensor delivers results within minutes and successfully distinguished healthy individuals from IBD patients in testing on 125 human plasma samples. The technology could enable faster, more accessible gut health monitoring, point-of-care diagnostics, wearable sensors, and personalized nutrition or therapeutic tracking, potentially bringing real-time microbiome function assessment into clinical practice.
Author: Abhay Panchal
Key Takeaways Automated text reminders were associated with a 9.0-percentage-point higher FIT completion rate than nurse-led telephone outreach in a randomized quality improvement trial of automated text reminders for FIT completion. The comparison took place across eight federally qualified health centers in Brooklyn, New York. Adults with a new FIT order received automated one-way text reminders or a nurse-led reminder call after the order was placed.
Most patients who undergo a combined upper and lower GI endoscopy think of it as one procedure. In clinical terms, it is two: an esophagogastroduodenoscopy examining the upper tract, followed by a colonoscopy examining the lower. The appeal of doing both in a single session is obvious. One preparation, one sedation event, and less time away from work or family. For health systems managing a specialist shortage that is projected to reach nearly 1,400 gastroenterologists by 2037, consolidating procedures wherever possible is moving from a convenience to a strategic necessity. But combined GI endoscopy is rarely framed as a deliberate…
Channel Robotics has raised $2.5 million in Seed+ funding, bringing its total funding to $4.6 million, to advance a handheld AI-enabled endoscopic robotic platform designed to work through existing flexible endoscopes. Unlike large robotic systems that require significant capital investment, the company’s approach aims to deliver robotic-level dexterity in a handheld format that could be adopted across hospitals, ASCs, and community GI practices. The funding will support product development, manufacturing, and regulatory activities, with an FDA submission targeted for 2027, reflecting continued investment in next-generation robotic technologies for minimally invasive GI procedures.
Gastroenterologists perform more procedures per physician than nearly any other specialty, and the volume carries risk. Colonoscopy remains the most litigated procedure in GI, but the landscape extends to ERCP (endoscopic retrograde cholangiopancreatography), missed diagnoses and wrong-patient errors. Here are five numbers that define where GI malpractice exposure stands: 0.34% to 2.5%: Rates of serious injury due to colonoscopies vary in research between 0.34% and 2.5%, according to a law firm Miller and Zois analysis. The risk of bowel perforation specifically is estimated at 0.2% to 1%. Perforation is the most litigated injury, but hemorrhage following polyp removal, splenic injury…
Researchers at Northwestern Medicine Digestive Health Center are building evidence that behavioral health interventions can play a critical role in managing GI disorders by targeting the gut-brain axis, hypervigilance, and symptom-specific anxiety. Studies from the group found that patients with conditions such as achalasia, GERD, IBS, Crohn’s disease, and colitis who experience higher levels of anxiety and symptom hypervigilance often report worse outcomes and lower quality of life, even after successful medical or surgical treatment. Researchers are now evaluating cognitive behavioral therapy and other gut-brain interventions to determine whether addressing these psychological factors can improve symptoms, reduce healthcare utilization, and…
The white paper spurred widespread adoption of the POWER program by academic and private gastroenterology and hepatology practices, many of which have used it as a guide for implementing a multidisciplinary obesity care model.2 The aim of this commentary is to provide a comprehensive update of POWER in light of several important developments in the fields of obesity and cardiometabolic diseases in recent years, including the following:
The article highlights a growing debate around AI-assisted colonoscopy: while AI consistently improves polyp and adenoma detection rates, much of the improvement comes from finding very small, low-risk lesions whose removal may have limited impact on long-term colorectal cancer outcomes. Meta-analyses show AI-assisted colonoscopy increases adenoma detection by about 37% and polyp detection by 36%, with some studies reporting gains of up to 50%. However, critics argue that AI disproportionately identifies diminutive polyps (<5 mm), which rarely progress to cancer. As a result, AI may inflate traditional quality metrics such as adenoma detection rate without necessarily reducing interval colorectal cancer…
Several studies presented at DDW 2026 highlighted emerging approaches that could reshape GI care, from less invasive Barrett’s esophagus surveillance to outpatient advanced endoscopy and digital therapies for pediatric abdominal pain. Researchers reported that capsule sponge testing detected high-grade dysplasia and esophageal adenocarcinoma more effectively than standard Barrett’s surveillance endoscopy, while a next-generation device improved patient tolerability. Another study found that outpatient endoscopic submucosal dissection (ESD) was safe and feasible in more than 1,000 patients, potentially reducing hospital admissions and resource use. Meanwhile, a four-week web-based program combining hypnosis and cognitive behavioral therapy helped reduce anxiety and somatic stress in…
A favorable HHS-OIG advisory opinion could accelerate interest in multi-cancer early detection (MCED) testing by allowing a company to provide a free supplemental multi-cancer risk report alongside a Medicare-covered colorectal cancer blood test. While regulators acknowledged the arrangement could raise anti-kickback concerns, they concluded the risk was low because the additional analysis uses the same blood sample, creates no extra cost to Medicare, and may provide clinically meaningful information for cancers that currently lack established screening options. The decision highlights growing regulatory openness to innovative cancer screening approaches while maintaining safeguards against inappropriate utilization and patient steering.